Lung cancer is the most common cause of cancer deaths. The expression of the transcription factor C/EBPa (CCAAT/ enhancer binding protein a) is frequently lost in non-small cell lung cancer, but the mechanisms by which C/EBPa suppresses tumor formation are not fully understood. In addition, no pharmacological therapy is available to specifically target C/EBPa expression. We discovered a subset of pulmonary adenocarcinoma patients in whom negative/low C/EBPa expression and positive expression of the oncogenic protein BMI1 (B lymphoma Mo-MLV insertion region 1 homolog) have prognostic value. We also generated a lung-specific mouse model of C/EBPa deletion that develops lung adenocarcinomas, which are prevented by Bmi1 haploinsufficiency. BMI1 activity is required for both tumor initiation and maintenance in the C/EBPa-null background, and pharmacological inhibition of BMI1 exhibits antitumor effects in both murine and human adenocarcinoma lines. Overall, we show that C/EBPa is a tumor suppressor in lung cancer and that BMI1 is required for the oncogenic process downstream of C/EBPa loss. Therefore, anti-BMI1 pharmacological inhibition may offer a therapeutic benefit for lung cancer patients with low expression of C/EBPa and high BMI1.
INTRODUCTION
Lung cancer accounts for 30% of tumor-related deaths (1) . Most patients are refractory to current treatments; therefore, understanding the mechanisms that control lung tumorigenesis is essential to design new therapies. One event that frequently occurs in primary non-small cell lung cancer (NSCLC) is the lack of expression of the transcription factor CCAAT/enhancer binding protein a (C/EBPa) by either hypermethylation (2) or genetic loss (3) . C/EBPa controls tissue-specific gene expression and promotes proliferation arrest in terminally differentiated cells from several tissues, including pulmonary cells (4) . C/ EBPa acts as a tumor suppressor in acute myeloid leukemia (4-7), and it is down-regulated in hepatic carcinogenesis (8) , squamous cell skin carcinomas (9) , and squamous cell cancers of the head and neck (10) and is dysregulated in prostate cancer (11) .
C/EBPa knockout mice display perinatal lethality with severe hypoglycemia and respiratory distress (12, 13) . Lung-specific in utero loss of C/EBPa results in delayed maturation of the lung, respiratory arrest, and lethality after birth, caused by epithelial cell expansion and loss of airspace (14, 15) . C/EBPa loss causes lack of differentiation, hyperproliferation, and increased survival of type II alveolar cells, with an overall down-regulation of genes involved in differentiation, and up-regulation of proliferation, tumor progression, and cell survival genes (14) . In addition, induction of C/EBPa expression in human lung cancer cells resulted in differentiation and growth reduction, attributable to proliferation arrest and apoptosis (16) .
The mechanisms by which C/EBPa suppresses tumor formation are unclear. No pharmacological therapy is available to specifically target the large subsets of patients with loss of C/EBPa expression.
We hypothesized that C/EBPa could be performing its protective function by helping to restrain the activity of critical proto-oncogenes. Similar to what we observed in C/EBPa −/− hematopoietic stem cells (17) , reciprocal expression between C/EBPa and BMI1 (B lymphoma Mo-MLV insertion region 1 homolog) also occurs in lung cancer. Here, we report that more than 80% of C/EBPa-negative/low adenocarcinoma patients are positive for the expression of the oncogenic protein BMI1 and that this expression pattern has prognostic value. By using short hairpin RNA (shRNA) against Bmi1 and a compound Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed on experimental samples (n = 3) from the human lung adenocarcinoma cell line H358 transfected with a rapamycininducible C/EBPa-expressing vector or a rapamycininducible empty vector (as control), and induced with rapamycin (for 36 hours). The mean expression is presented as a percentage of 18S RNA. The P values for each sample are indicated on the basis of a two-sided Welch's t test. Right: Western blot analysis was carried out in H358 cells transfected with the rapamycin-inducible C/EBPa-expressing vector or the rapamycininducible empty vector by using anti-C/EBPa and anti-BMI1 antibodies. Loading was assessed, after complete stripping of the membrane, with an anti-actin antibody. Patients are stratified according to low or high C/EBPa expression, defined as log 2 expression < 9.0 or not, respectively. Survival probability is higher (P = 0.041) in BMI1 low patients, as compared to BMI1 high patients in the C/EBPa low subgroup. The median expression of BMI1 used to define BMI1 low and BMI1 high patient subgroups was 10.2 in the C/EBPa low group and 10.1 in the C/ EBPa high group. The method of Kaplan and Meier was used for graphical displays of overall survival. The log-rank test was used to assess differences in overall survival. A similar approach was also applied for C/EBPa high samples. The P value and the sample size (n) for each subgroup are indicated on each plot. Among C/EBPa low patients, 30 death events/109 patients presented with low BMI1 expression, and 39 death events/ 109 patients presented with high BMI1 expression. Among C/EBPa high patients, 40 death events/136 patients presented with low BMI1 expression, and 39 death events/136 patients presented with high BMI1 expression. Asterisk indicates statistical significance.
that inhibits it, we demonstrated that BMI1 has a critical in vivo role in supporting and maintaining the transformed phenotype of C/ EBPa-null cells, pointing to the therapeutic potential of targeting BMI1 in C/EBPa-negative/low adenocarcinoma patients.
RESULTS
A subset of C/EBPa-negative/low and BMI1-positive human adenocarcinomas is amenable to BMI1 pharmacological inhibition To address the molecular mechanisms by which C/EBPa suppresses transformation, we analyzed gene expression profile changes of a human adenocarcinoma cell line (H358) after overexpression of an inducible form of C/EBPa (16) . Upon C/EBPa up-regulation, both BMI1 mRNA and protein were markedly reduced (Fig. 1A) . To investigate whether C/EBPa performs its tumor-suppressing function by restraining BMI1 expression, we examined the correlation between C/EBPa and BMI1 protein amounts in primary lung cancer patient specimens through immunohistochemistry (IHC fig. S1 (A to G). The adenocarcinoma cases (69.6%) were negative/low for C/EBPa expression (0, 1 + ), as previously described (16) , and 82.8% of them were positive for BMI1 expression (1 + to 3 + ) (Fig. 1B) . Examples of adenocarcinoma staining are presented in Fig. 1C . To investigate whether BMI1 expression correlates with prognosis in lung cancer for patients with negative/low C/ EBPa expression, we compared overall survival in 490 lung adenocarcinoma samples available in The Cancer Genome Atlas [TCGA; lung adenocarcinoma (LUAD) data set at https://tcga-data.nci.nih.gov/tcga/], as well as three different publicly available microarray expression databases (18) (19) (20) , containing data from additional 490 NSCLC patients. When the 490 TCGA adenocarcinoma patients were stratified according to absent/low C/EBPa expression, the survival difference between BMI1 low and BMI1 high lung cancers was in favor of BMI1 low patients (P = 0.041) (Fig. 1D ). All NSCLC microarray cohorts [ fig. S2 , A (n = 133, P = 0.044) and B (n = 181, P = 0.038)] showed a difference in survival between C/EBPa-negative/low BMI1 low and BMI1 high subgroups, except for the Tang et al. study (n = 176) ( fig. S2C) (20) .
Overall, our data show that more than 80% of C/EBPa-negative/ low adenocarcinomas display positive BMI1 expression and that this expression pattern has prognostic value. We have thus identified a molecular subtype of human adenocarcinomas, which may be amenable to BMI1 inhibition therapy.
C/EBPa is a tumor suppressor in lung cancer, and its loss correlates with increased BMI1 expression The observation that loss of C/EBPa is a common event in NSCLC (16) prompted us to study the in vivo consequences of C/EBPa deletion in adult lungs. We used the Clara Cell Secretory Protein (CCSP) promoter to drive conditional Cre recombinase-induced deletion of C/EBPa in pulmonary epithelial cells. Doxycycline-treated mice were referred to as C/EBPa Lung-D mice, to indicate their targeted C/EBPa deletion in lung cells ( fig. S3A ). Histopathologic analysis showed that 6 to 8 months after doxycycline treatment,~33% of the C/EBPa Lung-D mice did not express detectable amounts of C/EBPa RNA (Fig. 2B) . Similarly, IHC staining confirmed the absence of C/EBPa protein ( Fig. 2A, right panel) , and Southern blot assays demonstrated complete excision of the C/EBPa gene in tumors (Fig. 2C) . In summary, lung-specific deletion of C/ EBPa in adult lung epithelium facilitates adenocarcinoma formation, validating the hypothesis that C/EBPa acts as a pulmonary tumor suppressor in vivo. Murine primary adenocarcinomas displayed reciprocal expression between C/EBPa and BMI1 ( which was able to grow tumors upon subcutaneous injection into immunocompromised NSG (nonobese diabetic/severe combined immunodeficient/interleukin-2 receptor g null) mice ( fig. S3D ) and to form multiple pulmonary metastatic foci upon bloodstream injection ( fig. S3E ).
C/EBPa restrains BMI1 expression Retroviral introduction of C/EBPa in the murine C/EBPa-null pulmonary tumor cells was sufficient to decrease both Bmi1 mRNA ( Fig. 3A ) and protein expression (Fig. 3B ), suggesting that C/EBPa is involved in Bmi1 gene regulation. Similarly, overexpression of an inducible form of C/EBPa (16) in the human adenocarcinoma cell line H358 was able to decrease BMI1 expression by 83%, as compared to the empty vector control (Fig. 1A) , suggesting that repression of BMI1 by C/EBPa is conserved between murine and human pulmonary cells. Together, these data indicate that C/EBPa negatively affects BMI1 expression in lung cancer cells.
BMI1 is required for lung tumor initiation and maintenance
Next, we asked whether tumor initiation was affected in C/EBPa conditional lung knockout mice in the context of Bmi1 haploinsufficiency (Bmi1 WT/GFP ) ( fig. S4A ) (21) . These mice display a~50% reduction in Bmi1 RNA expression in Lin − lung cells, as compared to Bmi1
WT/WT mice ( fig. S4B ). Upon doxycycline treatment, C/ EBPa Lung-D × Bmi1 WT/WT mice (n = 26) developed tumors at the At day 30, each of the Bmi1-sh constructs was significantly different from controls, using a two-sided Welch's t test. In the control animals, tumor burden was 4.95 times that of day 10, compared to 1.69 times that of day 10 for Bmi1-sh1 (P = 0.0036), and 1.77 times that of day 10 for Bmi1-sh2 (P = 0.033). There was no difference between Bmi1-sh1 and Bmi1-sh2 (P = 0.453). 
expected incidence (34.6%), whereas C/EBPa
Lung-D animals with reduced BMI1 expression (n = 28), as well as control mice (n = 25), did not develop any tumors (Fig. 4A) , demonstrating that decreased BMI1 expression was sufficient to inhibit tumor formation. To test whether Bmi1 knockdown was sufficient to also affect tumor growth in already transformed cells, we performed subcutaneous transplantation assays in NSG mice. After transduction of the murine C/EBPa-null pulmonary tumor cells with green fluorescent protein (GFP)-coupled lentiviral shRNAs against Bmi1 (sh1 and sh2) or a control shRNA (sh-Luciferase), we verified that Bmi1 RNA (fig. S4C, left panel)  and protein expression (fig. S4C, right panel) was silenced in GFP + cells. Injection of cells displaying Bmi1 knockdown resulted in the formation of smaller tumors (Bmi1-sh1 versus control, P = 0.0001; Bmi1-sh2 versus control, P < 0.0001; Fig. 4B ), as well as a decreased percentage of mice with tumors (83.3% of Bmi1-sh1-infected and 66.6% of Bmi1-sh2-infected mice developed tumors, as compared to 100% of the Luc-sh-control-infected mice). At day 30, tumor growth was specifically affected in mice injected with Bmi1-sh1-infected (P = 0.036) or Bmi1-sh2-infected cells (P = 0.033), as compared to sh-Luciferase-infected cells (Fig. 4C) . At the time of harvest, GFP + tumor cells from both Bmi1-sh1-and Bmi1-sh2-infected cells maintained reduced Bmi1 expression ( fig. S4D ). At harvest, tumors derived from Bmi1-sh1-and Bmi1-sh2-infected cells were mainly GFP − , as compared to Luc-sh-control-derived tumors ( fig. S4 , E, lower panel, and F), suggesting that the tumors found in Bmi1-sh1 and Bmi1-sh2 grafts were derived from the small percentage (less than 3%, as shown in fig. S4 , E, upper panel, and F) of nontransduced (GFP − ) cells that have outgrown the GFP + population when co-injected into the NSG mice. Murine C/EBPa-null pulmonary tumor cells transduced with a GFP-coupled retroviral construct to overexpress C/EBPa (MSCV-C/EBPa) demonstrated a 50% decrease in BMI1 expression as compared to control vector (MSCV)-transduced cell (Fig. 3A) . Therefore, we assessed their ability to grow tumors in subcutaneous transplantation assays in NSG mice. Injection of GFP + MSCV-C/ EBPa-transduced cells resulted in the formation of smaller tumors at day 30 (P = 0.0077), as compared to GFP + MSCV-transduced cells (Fig. 4D) . Overall, these data indicate that BMI1 is required to maintain the transformed phenotype of C/EBPa-null pulmonary cancer cells and allow their growth.
BMI1 inhibition therapy reduces tumor growth in lung tumorigenesis
We next investigated whether modulation of BMI1 expression was sufficient to reduce tumor burden. To devise a targeted therapy to antagonize the oncogenic effect of BMI1, we used a compound (PTC-209) ( fig. S5A ) capable of reducing BMI1 translation (22) . PTC-209 is a low-molecular weight molecule identified by high-throughput screening of compounds using gene expression modulation by small molecules (GEMS) technology, in which the GEMS reporter vector contains the luciferase open reading frame flanked by and under posttranscriptional control of the BMI1 5′ and 3′ untranslated regions (22) . Western blots of the C/EBPa-null line exposed to increasing concentration of PTC-209 (0.7 and 1.5 mM) or 0.5% dimethyl sulfoxide (DMSO) control showed that BMI1 protein was efficiently decreased in a dose-dependent manner (Fig. 5A) , to 35 and 5% that of DMSOtreated cells, respectively ( fig. S5B ). BMI1 is a key component of the epigenetic complex PRC1 (Polycomb repressive complex 1), and other components of the PRC1/2 complex (RING1, EZH1, EZH2, and EED) were unaffected ( fig. S5C, upper panel) or just mildly affected (SUZ12) by PTC-209 treatment ( fig. S5C, lower panel) . PTC-209 treatment was also accompanied by a slightly increased histone 3 with trimethylated lysine 27 and by abrogation of histone 2A lysine 119 ubiquitination, as expected, because BMI1 catalyzes the H2AK119Ub modification ( fig. S5C, lower panel) . Gene expression profiling and gene set enrichment analysis (GSEA) of C/EBPa-null cells exposed to PTC-209 (1.5 mM) or DMSO control showed enrichment of BMI1 target genes (Fig. 5B) . Specifically, most BMI1-activated targets (23) were down-regulated in PTC-treated cells (P = 0.002), and most genes repressed by BMI1 (23) were up-regulated with PTC treatment (P < 0.001). These results corroborate the observation that PTC-209 effectively inhibits BMI1 protein expression (Fig. 5A) and that Bmi1 mRNA is also down-regulated upon PTC-209 treatment ( fig. S5D) .
Further, we observed that BMI1 in vitro inhibition resulted in an increased percentage of C/EBPa-null lung cancer cells arrested in a nondividing state (Fig. 5C) , which prompted us to test PTC-209 effects on in vivo tumor maintenance. After developing measurable tumors, NSG mice were treated daily with PTC-209 or vehicle control for 1 month. Tumor growth was specifically affected in PTC-209-treated animals (n = 6), in which the tumor burden was decreased by 70% (P = 0.00001) compared to that observed in vehicle-treated mice (n = 6) (Fig. 5D ). PTC-209 treatment altered the cell cycle profile, with BMI1 in vivo inhibition consistently showing an increase in cells in G 0 phase (average of 76.9 ± 2.3% in PTC-209-treated compared to 39.1 ± 8.7% in vehicle-treated cells, P = 0.002), as shown in Fig. 5E .
A panel of human NSCLC cell lines (adenocarcinoma cell lines H322, A549, H23, H1975, H358, PC9, Calu-3, H1755, and H1650; adenosquamous carcinoma cell line H647; bronchial carcinoid cell line H727; and carcinoma cell lines Calu-1 and H1299) expressed almost undetectable amounts of C/EBPa and medium/high amounts of BMI1 ( fig. S5E ). We could not identify any NSCLC cell line with substantial expression of C/EBPa. In contrast, C/EBPa was expressed in medium/high amounts in the breast cancer cell line MDA-231 and in the ovarian cancer cell lines Ovcar-3, Skov3, and 36M2, which all had medium to low amounts of BMI1 expression ( fig. S5E ).
Upon treatment of the adenocarcinoma cell lines H322, A549, H23, H1975, H358, and PC9 with PTC-209 (1.5 mM) or DMSO control for 48 hours, the amount of BMI1 protein decreased across the six cell lines to a mean of 5.49% of the expression in the absence of the inhibitor (SD, 2.39) (Fig. 5F ), and PTC-209 treatment increased the percentage of cells arrested in a nondividing state in all the human adenocarcinoma cell lines analyzed ( fig. S5F) . Consistently, when mice xenografted with the human adenocarcinoma cell lines were treated with daily injections of PTC-209, they all responded to BMI1 in vivo inhibition treatment, showing a significant tumor growth reduction (P = 0.037 for H322 cells, P = 0.025 for A549 cells, P = 0.026 for H23 cells, P = 0.026 for H1975 cells, P = 0.042 for H358 cells, and P = 0.032 for PC9 cells), as compared to vehicle-treated mice (Fig. 5G) . Overall, our data suggest that BMI1 is a critical and druggable target, because PTC-209 effectively reduced tumor growth and maintenance in C/ EBPa-null/low tumors positive for BMI1 expression.
DISCUSSION
A better understanding of the heterogeneity of lung cancer may produce innovations in treatment strategies to potentially overcome resistance, relapse, and progression of the cancer. Previously, we have shown that C/EBPa expression is frequently decreased/abrogated in human lung cancers (4, 16) . We have also suggested that the loss of C/EBPa could be an important event in the multistep program of transformation (14) . However, the key molecular events required for C/EBPa-deficient cells to trigger lung tumorigenesis were still unclear. Here, we identified a subset of C/EBPa-negative/low adenocarcinoma patients, in which we observed an inverse correlation of C/EBPa and BMI1 expression. We highlighted the therapeutic potential of targeting BMI1 in this subset of patients by describing a compound that inhibits BMI1 and blocks its oncogenic role. We generated mice with specific targeted deletion of C/EBPa in adult lung epithelium, which developed pulmonary adenocarcinomas with 33% penetrance, thus establishing C/EBPa as a bona fide lung tumor suppressor in vivo. Tumors growing in the murine model recapitulated the abnormal expression of the C/EBPa/BMI1 axis observed in more than 80% of C/EBPa-negative/ low adenocarcinoma patients, confirming that they are an important preclinical tool. We showed that C/EBPa-null tumor formation is dependent on the presence of two functional Bmi1 alleles, implying that Bmi1 gene dosage is a critical checkpoint that lung cells must overcome to achieve transformation.
BMI1 is a key component of the epigenetic complex PRC1, which is frequently overexpressed in human cancers, including NSCLCs, lymphomas, leukemias, neuroblastoma, skin tumors, and breast and colorectal carcinomas (24) (25) (26) (27) (28) (29) (30) (31) (32) . BMI1 inhibition was recently found to reduce tumor burden in human colorectal xenograft models (22) , similarly to what we observed in lung cancer. Specifically, by knocking down Bmi1, a gene that lies at the heart of stem cells' self-renewal machinery (33), Kreso et al. observed a decrease in human colon cancer tumor mass in mouse xenografts, as well as a decrease in the total number of tumors initiated, suggestive of BMI1's role in regulating cancer-initiating cells (22) . Thus, identification of factors modulating BMI1 expression has generated major clinical interest. Among the mechanisms proposed to affect its expression, BMI1 copy number was analyzed in NSCLCs but found to be unchanged (32) . Chromosomal aberrations that may result in up-regulation of BMI1 expression were shown in a case of T cell acute lymphoblastic leukemia (34) . Increased gene transcription of BMI1 has been described in Hodgkin's lymphoma cell lines, in which nuclear factor kB signaling contributes to its up-regulation (35) . In breast and gastric cancers, BMI1 expression is repressed by MEL-18, a Polycomb gene with tumor suppressor activity (36) . Nonetheless, the exact mechanisms controlling BMI1 upregulation in lung cancer and other epithelial tumors remain unidentified. Because our data indicate that C/EBPa contributes to inhibit BMI1 expression, we propose that reducing C/EBPa protein relieves its repressive activity on BMI1 transcription. We showed that inhibition of BMI1 expression by shRNA in tumorigenic C/EBPa-null cells impairs their tumor-propagating ability. Similarly, pharmacological inhibition of BMI1 protein impairs lung tumor growth in C/EBPa-deficient/low cells by efficiently decreasing cell cycle progression, demonstrating the role of BMI1 in the transformed phenotype of C/EBPa-null/low tumor cells. In addition, we observed that BMI1 expression correlates with prognosis among CEBPa-null/low lung adenocarcinoma patients.
Further studies will be needed to elucidate the molecular mechanism through which C/EBPa loss contributes to pulmonary tumorigenesis. C/EBPa may repress BMI1 through down-regulation of c-MYC. C/EBPa directly represses c-MYC in human myeloid cells (37) . Conversely, stable overexpression of c-MYC results in an up-regulation of BMI1 expression, whereas knockdown of c-MYC results in a substantial down-regulation of the endogenous BMI1 expression in the human fibrocystic breast epithelial cell line MCF10A (36) . MEL-18 down-regulates BMI1 expression in breast and gastric cancers via c-MYC repression (36) and may be involved in this regulatory loop.
Down-regulation/inactivation of C/EBPa is a required step in the development of several tumor types in addition to NSCLC, making its downstream effectors potential markers and therapeutic targets. Loss of C/EBPa in keratinocytes contributes through yet unknown mechanisms to the accumulation of ultraviolet light B-induced mutations and accelerates skin cancer progression (38) . In hematopoietic malignancies, C/EBPa modulates cell growth through repression of oncogenes c-Myc, N-Myc, Bmi1, and Sox4 (17, 37, 39, 40) . We hypothesize that the C/EBPa/BMI1 axis will be central to cancer cell biology in other malignancies as well, given the numerous reports underlining both decreased activity of C/EBPa and increased expression of BMI1 in many cancer types (4, 7, 41) .
In conclusion, our studies show that C/EBPa is a tumor suppressor in lung cancer and that BMI1 is a downstream mediator of the oncogenic process. This suggests that the lung cancer subtype defined by the loss of C/EBPa expression might specifically benefit from BMI1 inhibitory therapy, which is being evaluated in a clinical trial (clinical trial identifier NCT02404480 at ClinicalTrials.gov). Because BMI1 plays a substantial role in many solid tumors, including one of the most aggressive models of lung cancer, defined by inducible expression of mutated K-Ras (42) , and its expression is positively correlated with tumor growth, invasion, metastasis, prognosis, and recurrence (43), our findings are of interest to help design better therapeutics for oncologic cancer patients displaying a positive BMI1 signature.
MATERIALS AND METHODS
Detailed protocols are provided in Supplementary Materials and Methods.
Study design
The objective of this study was to assess the physiological consequences of the genetic deletion of C/EBPa in lung epithelial cells. A murine pulmonary-specific C/EBPa conditional knockout model was generated to study the tumor suppressor function of C/EBPa.
The numbers of mice required for the experiments depicted in Fig. 4  and fig. S3 were not based on differences identified a priori, nor were formal power calculations done before conducting those experiments. In the experiment using 28 Bmi1-haploinsufficient C/EBPa Lung-D mice and 26 C/EBPa Lung-D mice with normal Bmi1 expression (Fig. 4A) , there would have been 86% power by Fisher's exact test to distinguish between a 30% rate of tumor in the 26 C/EBPa Lung-D mice with normal Bmi1 expression and a 1% rate of tumor in the 28 Bmi1-haploinsufficient C/EBPa Lung-D mice, testing at the 0.05 two-sided level. In the experiment that uses 102 C/EBPa Lung-D mice and 58 C/ EBPa Lung-D (heterozygous) mice (Fig. 3B) , there would have been greater than 99% power to detect a difference in the rate of tumor formation of 30% compared to 1%, using Fisher's exact test and testing at the 0.05 two-sided level of significance.
shRNA-mediated or pharmacological inhibition of BMI1 was also evaluated to determine BMI1's role as a therapeutic target in C/EBPanegative/low adenocarcinoma xenografts. Replicate experiments were performed two or three times. For drug treatments, animals were randomly assigned to treatment. Mice were randomized into various groups, but the experimenter was not blinded to the identities of individual groups. All collected data were used in statistical analyses. Exact numbers for each experiment are included in the figure legends. All of the mouse studies were approved by ethical committees of the Beth Israel Deaconess Medical Center. IHC data were independently and blindly scored by two pathologists.
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